Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why doing good also makes us feel good, during the holidays and beyond - 2Bother Control Administrations for 2024: Decide for Your Home
- 3RFK Jr. says he's following 'gold standard' science. Here's what to know
- 421 Incredibly Entertaining Contemplations To Observe Consistently
- 5IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- New heart disease calculator predicts 30-year risk for young adults
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- The Way to Business: Startup Illustrations Learned
- Doggie diversity in size and shape began at least 11,000 years ago
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Fake new headlights rule steer Australian drivers astray
- Vote In favor of Your Favored Menial helper Administration
- Strength training is crucial after menopause. How to make the most of your workouts
